the article blasting AMPE is working well to help the shorts cover their position before major news hits
First of all, I love your handle goinggreen.
I have done more due diligence on this company then even the analyst at Aegis whose report had a few major flaws and was far too conservative. I spoke with him at length and he admitted that he was forced to be ultra conservative by his company.
As far as the value of the drugs . . . Zertane already passed a large phase II trial in Europe. Biovale did give up on the trial but there was a different reason than what we hear the bears say. The real reason is that BV was under a corporate wide mandate to abandon ALL R&D trials that were not pivotal and Zertane was one at the time. When they abandoned it and it reverted back to AMPE, BV did not even look at the trial data. If they did, they would have fought to keep it. The trial results were a smashing success. Please allow me to attempt to translate Macaluso's presentation from last week. AMPE already completed that portion leading to the current pivotal phase III trial in the U.S. that has to do with creating the questionnaire for the patients in the trial. The questionnaire must be accepted by the FDA before the company can execute the final trial. The company has a major pharma partner ready to announce a deal as soon as the FDA announces formal acceptance of the questionnaire. They might accept it or they might reject it. My guess is that since the FDA already provided guidance for this pivotal trial, the company probably had a pretty good idea as to how to word the questionnaire. Therefore, it seems more probable that the FDA will soon announce acceptance that will clear the way for the company to make a major announcement that will likely send shares soaring. In fact, I believe very strongly that the new SA article blasting AMPE was put out by the shorts so they can cover their short position at low prices before the stock rockets and kills them. Anything can happen, but that is my take.
Then there is Ampion . . . and Optina . . . and NCE001 . . . and ORP . . . and 150 more compounds that they own. I have personally interviewed the senior director who ran the phase II trial in Australia and if you heard the results you would be buying all the shares at any price. I predict that Ampion is going to become the new standard in the Anti Inflammatory market and become a mega blockbuster.
Optina is going to destroy Lucentis and Eyelea. In fact, REGN is going to get hammered when Optina gets approved. When you read the prior results and when you understand the mechanism of how it works, it is light years better than anything in the market.
Management is not going to sell their shares at these ridiculously low prices unless one of them goes personally bankrupt and needs money.
Putting Zertane aside until we hear from the FDA on the questionnaire, Ampio and Optina are both ready to start trials that are only 12 weeks. That's fast. Look at any stock 12 months prior to FDa approval and you'll see an explosion. AMPE is just about at that point.
NCE001 is getting accelerated and it is an entirely new class of cancer treatment that is going to make big headlines in the next year. This one will be bigger than Texas.
And ORP is about to surprise very big.
Love what the shorts do to provide more liquidity but you have to be a mental case to be short this $4 stock. When it happens it will be instantaneously fast with no warning and it is going to be extremely painful to the shorts.
I know it seems like a long time but in my opinion if you can just stop listening to all the noisey chatter from traders who NEVER make a dime for very long, you will be rewarded HUGELY. It's only the holders who wind up making the big money. The traders have a lot of fun but at the expense of big and sustained profits. Never met one who lasted more than a few years unless they keep burning other peoples money.
Just my opinion and i know this company FAR better than anyone outside of the company and they don't know how to talk to investors and they certainly don't know how to tell their story because if they did, their stock would be miles higher today and not under pressure from some small time short sleezebags who take candy from babies.
Maybe they will get back on track of getting their real story out to investors who would love to know the truth.